Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?

ABSTRACT: The current landscape of therapeutics designed to treat multiple sclerosis (MS) and its pathological sequelae is saturated with drugs that modify disease course and limit relapse rates. While these small molecules and biologicals are producing profound benefits to patients with reductions in annualized relapse rates, the repair or reversal of demyelinated lesions with or without axonal damage, remains the principle unmet need for progressive forms of the disease. Targeting the extracellular pathological milieu and the signaling mechanisms that drive neurodegeneration are potential means to achieve neuroprotection and/or repair in the central nervous system of progressive MS patients. The Nogo-A receptor-dependent signaling mechanism has raised considerable interest in neurological disease

SUBMITTER: Kim MJ 

PROVIDER: S-EPMC6357095 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature